^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | letrozole (Aromatase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
HER2 Negative Breast Cancer: Invasive Breast Cancer…SYSTEMIC THERAPY FOR ER - AND/OR PR - POSITIVE RECURRENT OR STAGE IV (M1) DISEASE…HER2-Negative and Postmenopausal or Premenopausal Receiving Ovarian Ablation or Suppression…First-Line Therapy...Non-steroidal aromatase inhibitor (anastrozole, letrozole)...
Source:
Title:
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
Excerpt:
...- ER or PR positive ,cT2-3N0 or cT1-3/N+ M0 (ER-positive ≥1% nuclear staining by immunohistochemistry , Allred score≥3 )...
Trial ID:
Source:
Title:
An unblinded clinical trial for the treatment of a particular subtype of postmenopausal breast cancer where the patient will receive at random either Afatinib plus Letrozole or Letrozole alone Ensayo clínico para el tratamiento de pacientes postmenopáusicas con un subtipo particular de cáncer de mama en el que las pacientes podrán recibir (mediante asignación al azar) Afatinib más Letrozol o Letrozol solo.
Excerpt:
...5.ER positive breast cancer. ...
Trial ID:
More C2 evidence
Source:
Title:
A single-arm, multicenter, exploratory clinical study of CDK4/6 inhibitor combined with letrozole in preoperative treatment of stage II-III HR+, HER2- breast cancer (Luminal type)
Excerpt:
......
Trial ID:
Source:
Title:
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
Excerpt:
...- Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory....
Trial ID:
Source:
Title:
response evalutation of breast cancer treated with anti-endocrine drugs by means of biological biomarkers (miRNA-100) valutazione dellla risposta al trattamento del tumore della mammella con farmaci endocrini mediante marcatori biologici (miRNA-100)
Excerpt:
...Tumor of luminal immunophenotype A or B, according to ESMO guidelines (Luminal A: ER positive, Ki67 <20%, PgR> 20%; Luminal B; ER positive and Ki67=20% or PgR <20%, or both9. ...
Trial ID:
Source:
Title:
A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
Excerpt:
...- The tumor must be estrogen receptor positive...
Trial ID:
Source:
Title:
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
Excerpt:
...Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory....
Trial ID:
Source:
Title:
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
Excerpt:
...- ER positive breast cancer....
Trial ID:
Source:
Title:
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
Excerpt:
...- Estrogen receptor-positive tumor by immunohistochemistry (IHC)...
Trial ID:
Source:
Title:
Neoadjuvant Endocrine Therapy in Breast Cancer
Excerpt:
...ER-positive (≥50%), PgR-positive (≥50% ), HER2-negative, and previously untreated, non-metastatic primary invasive BC....
Trial ID:
Source:
Title:
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer
Excerpt:
...- Postmenopausal women with diagnosis of breast cancer, metastatic disease or locally advanced disease / Estrogen Receptor positive and HER-2 negative / candidate to receive Letrozole...
Trial ID:
Less C2 evidence
Source:
Title:
63O - Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment in luminal breast cancer: survival results of the UNICANCER-NeoPAL study
Published date:
05/03/2021
Excerpt:
Postmenopausal women with ER-positive, HER2-negative...were randomly assigned to either letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks (LETPAL)...40 months PFS rate is 86.7% (78.0-96.4) and 87.2% (78.1-97.4) in LETPAL and CT arms respectively....LETPAL strategy, together with selected postoperative administration of chemotherapy, may spare chemotherapy in some pts with LBC...
Trial ID:
Source:
Title:
Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer
Published date:
11/28/2020
Excerpt:
...we investigated the association of the score between good response group (R) and non-response group (NR) to endocrine therapy with letrozole in GSE20181 cohort (Figure 5A, n = 176)....Patients with high scores ER-positive/HER2-negative breast cancer have significantly better DFS and DSS in treatment group, but not in the non-treatment group in the METABRIC cohort.
DOI:
10.3390/cancers12123557
